Fmr LLC Moon Lake Immunotherapeutics Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Fmr LLC holds 3,644,009 shares of MLTX stock, worth $170 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,644,009

Previous 4,370,652 16.63%

Holding current value

$170 Million

Previous $220 Million 27.02%

% of portfolio

0.01%

Previous 0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$38.43 - $48.6 $27.9 Million - $35.3 Million	-726,643 Reduced 16.63%	3,644,009 $160 Million
Q1 2024 May 13, 2024	BUY	$43.78 - $63.86 $22.9 Million - $33.4 Million	522,974 Added 13.59%	4,370,652 $220 Million
Q4 2023 Feb 13, 2024	BUY	$36.35 - $63.02 $16.4 Million - $28.4 Million	450,425 Added 13.26%	3,847,678 $232 Million
Q3 2023 Nov 13, 2023	BUY	$48.35 - $61.26 $943,211 - $1.2 Million	19,508 Added 0.58%	3,397,253 $194 Million
Q2 2023 Aug 11, 2023	BUY	$19.01 - $51.79 $55.2 Million - $150 Million	2,902,313 Added 610.46%	3,377,745 $172 Million
Q1 2023 May 11, 2023	BUY	$11.03 - $23.7 $3.2 Million - $6.87 Million	289,932 Added 156.3%	475,432 $10.2 Million
Q4 2022 Feb 13, 2023	SELL	$7.05 - $10.5 $4.47 Million - $6.65 Million	-633,677 Reduced 77.36%	185,500 $1.95 Million
Q3 2022 Nov 10, 2022	SELL	$5.25 - $9.27 $1.96 Million - $3.47 Million	-374,113 Reduced 31.35%	819,177 $6.52 Million
Q2 2022 Aug 12, 2022	BUY	$4.69 - $13.25 $5.6 Million - $15.8 Million	1,193,290 New	1,193,290 $6.26 Million

Others Institutions Holding MLTX

# of Institutions

127

Shares Held

58.2M

Call Options Held

102K

Put Options Held

75.9K

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.73B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account